Breathprints for Breast Cancer: A Non‐Invasive Approach to BI‐RADS 4 Risk Stratification
Authors:
- Ashok Prabhu MasilamaniAMAshok Prabhu Masilamani
- Jayden K. HooperJHJayden K. Hooper
- Hafizur RahmanHRHafizur Rahman
- Romy PhilipRPRomy Philip
- Palash KaushikPKPalash Kaushik
- Geoffrey GrahamGGGeoffrey Graham
- Hélène Yockell-LelièvreHYHélène Yockell-Lelièvre
- Mojtaba Khomami AbadiMAMojtaba Khomami Abadi
- Sarkis H MeterissianSMSarkis H Meterissian
Preprint
- 1 December 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Breast cancer is the most common malignancy among women, and early detection is critical for improving outcomes. The Breast Imaging Reporting and Data System (BI-RADS) standardizes reporting, but the BI-RADS 4 category presents a major challenge, with malignancy risk ranging from 2% to 95%. Consequently, most women in this category undergo biopsies that ultimately prove unnecessary. This study evaluated whether exhaled breath analysis could distinguish malignant from benign findings in BI-RADS 4 patients. Methods: Participants referred to the McGill University Health Centre Breast Center with BI-RADS 3–5 findings provided multiple breath specimens. Breathprints were captured using an eNose powered breathalyzer , and diagnoses were confirmed by imaging and pathology. An autoencoder-based model fused the breath data with BI-RADS scores to predict malignancy. Model performance was assessed using repeated cross-validation with ensemble voting, prioritizing sensitivity to minimize false negatives. Results: The breath specimens of eighty-five participants, including sixty-eight patients with biopsy-confirmed benign lesions and seventeen patients with biopsy-confirmed breast cancer within the BI-RADS 4 cohort are analyzed. The model achieved a mean sensitivity of 88%, specificity of 75%, and a negative predictive value of 97%. Results were consistent across BI-RADS 4 subcategories, with particularly strong sensitivity in higher-risk groups. Conclusions: This proof-of-concept study shows that exhaled breath analysis can reliably differentiate malignant from benign findings in BI-RADS 4 patients. With its high negative predictive value, this approach may serve as a non-invasive rule-out tool to reduce unnecessary biopsies, lessen patient burden, and improve diagnostic decision-making. Larger, multi-center studies are warranted.Keywords
All Related Versions
- Version 1, 2025-12-01, Preprints
- Published version: Cancers, 18 (2), 226.
This publication has 25 references indexed in Scilit:
- Analysis of Breast Cancer Mortality in the US—1975 to 2019JAMA, 2024
- Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breathCritical Reviews in Clinical Laboratory Sciences, 2022
- Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound examsNature Communications, 2021
- Fusion of medical imaging and electronic health records using deep learning: a systematic review and implementation guidelinesnpj Digital Medicine, 2020
- BI-RADS ® fifth edition: A summary of changesDiagnostic and Interventional Imaging, 2017
- Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled MoleculesACS Nano, 2016
- Detection of volatile organic compounds (VOCs) from exhaled breath as noninvasive methods for cancer diagnosisAnalytical and Bioanalytical Chemistry, 2015
- A profile of volatile organic compounds in breath discriminates COPD patients from controlsRespiratory Medicine, 2010
- Analysis of exhaled breath from smokers, passive smokers and non‐smokers by solid‐phase microextraction gas chromatography/mass spectrometryBiomedical Chromatography, 2008
- Breast imaging reporting and data system (BI-RADS)Radiologic Clinics of North America, 2002